Cosentyx may soon share the hidradenitis suppurativa (HS) field with another inflammatory biologic—but, for now, the Novartis drug has a head start. That’s good news for the Swiss Pharma, given that ...

The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections for treating various inflammatory conditions in adults and, in some cases, children. Cosentyx may treat moderate ...

Novartis’ immunology drug Cosentyx (secukinumab) notched its sixth indication, gaining U.S. approval as a hidradenitis suppurativa (HS) therapy, the drugmaker said this week. The regulatory OK makes ...

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Novartis (SWX:NOVN) reported that its drug Cosentyx achieved significant Phase III results ...

Please note NiYondashay is a COSENTYX ® (secukinumab) patient and has been compensated for her time. Continue reading for Important Safety Information and a link to the full Prescribing Information ...

By Bhanvi Satija LONDON, July 20 (Reuters) - Novartis investors will look beyond Tuesday's quarterly results for indications ...

The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections to treat several inflammatory conditions. Adults and certain children can receive this medication to treat ...

Celltrion has launched its push into the North American market with a biosimilar candidate targeting one of the world's largest autoimmune disease drugs — ...

DENVER (KDVR) — A Colorado board continues reviewing the cost of prescription drugs, and public feedback is wanted about the latest two under review. Cosentyx, which treats psoriasis, and Stelara, for ...

FRANKFURT, July 18 (Reuters) - Swiss drugmaker Novartis (NOVN.S), opens new tab raised its 2024 earnings guidance for the second time on Thursday, driven by a gain in prescriptions for drugs including ...